Rakovina Therapeutics Stock Performance
| RKV Stock | CAD 0.08 0.01 11.11% |
Rakovina Therapeutics has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of -0.45, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Rakovina Therapeutics are expected to decrease at a much lower rate. During the bear market, Rakovina Therapeutics is likely to outperform the market. Rakovina Therapeutics right now holds a risk of 7.8%. Please check Rakovina Therapeutics treynor ratio and the relationship between the semi variance and period momentum indicator , to decide if Rakovina Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Rakovina Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Rakovina Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
1 | Rakovina Therapeutics Teams Up with Variational AI for Cancer Drug Discovery - TipRanks | 09/17/2024 |
2 | Rakovina Therapeutics Showcases AI in Cancer Therapy - TipRanks | 11/20/2024 |
| Begin Period Cash Flow | 896.8 K |
Rakovina |
Rakovina Therapeutics Relative Risk vs. Return Landscape
If you would invest 9.00 in Rakovina Therapeutics on September 3, 2024 and sell it today you would lose (1.00) from holding Rakovina Therapeutics or give up 11.11% of portfolio value over 90 days. Rakovina Therapeutics is currently producing 0.1148% returns and takes up 7.7978% volatility of returns over 90 trading days. Put another way, 69% of traded stocks are less volatile than Rakovina, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Rakovina Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rakovina Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rakovina Therapeutics, and traders can use it to determine the average amount a Rakovina Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0147
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | RKV |
| Negative Returns |
Estimated Market Risk
| 7.8 actual daily | 69 69% of assets are less volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Rakovina Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rakovina Therapeutics by adding it to a well-diversified portfolio.
Rakovina Therapeutics Fundamentals Growth
Rakovina Stock prices reflect investors' perceptions of the future prospects and financial health of Rakovina Therapeutics, and Rakovina Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rakovina Stock performance.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 8.11 M | ||||
| Shares Outstanding | 90.29 M | ||||
| Price To Book | 2.13 X | ||||
| EBITDA | (2.16 M) | ||||
| Net Income | (2.61 M) | ||||
| Cash And Equivalents | 4.37 M | ||||
| Cash Per Share | 0.06 X | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (1.86 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Total Asset | 5.15 M | ||||
| Retained Earnings | (10.93 M) | ||||
About Rakovina Therapeutics Performance
Evaluating Rakovina Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Rakovina Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rakovina Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Certain Worldwide Rights of NewGen Therapeutics, Inc. comprises PARP inhibitor program technology. RAKOVINA THERAPEUTICS is traded on Commodity Exchange in Exotistan.Things to note about Rakovina Therapeutics performance evaluation
Checking the ongoing alerts about Rakovina Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rakovina Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rakovina Therapeutics had very high historical volatility over the last 90 days | |
| Rakovina Therapeutics has some characteristics of a very speculative penny stock | |
| Rakovina Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rakovina Therapeutics has accumulated about 4.37 M in cash with (1.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Rakovina Therapeutics Showcases AI in Cancer Therapy - TipRanks |
- Analyzing Rakovina Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rakovina Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rakovina Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rakovina Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rakovina Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rakovina Therapeutics' stock. These opinions can provide insight into Rakovina Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.